Abstract
Patients with COVID-19 are sometimes already being treated for one or more other chronic conditions, especially if they are elderly. Introducing a treatment against COVID-19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug-drug interactions. Here, we analyzed the potential or proven risk of the co-administration of drugs used for the most common chronic diseases and those currently offered as treatment or undergoing therapeutic trials for COVID-19. Practical recommendations are offered, where possible.
Keywords:
adverse events; hydroxychloroquine; lopinavir; pharmacodynamics; pharmacokinetics; therapeutic drug monitoring.
© 2020 Société Française de Pharmacologie et de Thérapeutique.
MeSH terms
-
Analgesics / pharmacology
-
Anti-Asthmatic Agents / pharmacology
-
Anti-Bacterial Agents / pharmacology
-
Anti-Inflammatory Agents / pharmacology
-
Anticoagulants / pharmacology
-
Antineoplastic Agents / pharmacology
-
Antitubercular Agents / pharmacology
-
Antiviral Agents / pharmacology
-
Betacoronavirus
-
COVID-19
-
COVID-19 Drug Treatment
-
Cardiovascular Agents / pharmacology
-
Coronavirus Infections / drug therapy*
-
Drug Interactions
-
Humans
-
Hydroxychloroquine / pharmacology
-
Hypoglycemic Agents / pharmacology
-
Hypolipidemic Agents / pharmacology
-
Interferon beta-1b / pharmacology
-
Pandemics
-
Pneumonia, Viral / drug therapy*
-
Prescription Drugs / pharmacokinetics
-
Prescription Drugs / pharmacology*
-
Psychotropic Drugs / pharmacology
-
Receptors, Interleukin / antagonists & inhibitors
-
Risk Assessment
-
SARS-CoV-2
-
Thyroid Hormones / pharmacology
Substances
-
Analgesics
-
Anti-Asthmatic Agents
-
Anti-Bacterial Agents
-
Anti-Inflammatory Agents
-
Anticoagulants
-
Antineoplastic Agents
-
Antitubercular Agents
-
Antiviral Agents
-
Cardiovascular Agents
-
Hypoglycemic Agents
-
Hypolipidemic Agents
-
Prescription Drugs
-
Psychotropic Drugs
-
Receptors, Interleukin
-
Thyroid Hormones
-
Interferon beta-1b
-
Hydroxychloroquine